237 related articles for article (PubMed ID: 12069959)
1. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.
Loemba H; Brenner B; Parniak MA; Ma'ayan S; Spira B; Moisi D; Oliveira M; Detorio M; Wainberg MA
Antimicrob Agents Chemother; 2002 Jul; 46(7):2087-94. PubMed ID: 12069959
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance.
Loemba H; Brenner B; Parniak MA; Ma'ayan S; Spira B; Moisi D; Oliveira M; Detorio M; Essex M; Wainberg MA
Antiviral Res; 2002 Nov; 56(2):129-42. PubMed ID: 12367719
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations.
Eshleman SH; Jones D; Galovich J; Paxinos EE; Petropoulos CJ; Jackson JB; Parkin N
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):289-93. PubMed ID: 16545016
[TBL] [Abstract][Full Text] [Related]
4. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
5. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.
Brenner B; Turner D; Oliveira M; Moisi D; Detorio M; Carobene M; Marlink RG; Schapiro J; Roger M; Wainberg MA
AIDS; 2003 Jan; 17(1):F1-5. PubMed ID: 12478089
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.
Bacheler LT; Anton ED; Kudish P; Baker D; Bunville J; Krakowski K; Bolling L; Aujay M; Wang XV; Ellis D; Becker MF; Lasut AL; George HJ; Spalding DR; Hollis G; Abremski K
Antimicrob Agents Chemother; 2000 Sep; 44(9):2475-84. PubMed ID: 10952598
[TBL] [Abstract][Full Text] [Related]
7. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
Hu Z; Kuritzkes DR
J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
[TBL] [Abstract][Full Text] [Related]
8. [Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors resistant HIV-1].
Cao YL; Li SX; Chen H; Guo Y
Yao Xue Xue Bao; 2009 Apr; 44(4):355-61. PubMed ID: 19545051
[TBL] [Abstract][Full Text] [Related]
9. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
Xu HT; Colby-Germinario SP; Huang W; Oliveira M; Han Y; Quan Y; Petropoulos CJ; Wainberg MA
Antimicrob Agents Chemother; 2013 Nov; 57(11):5649-57. PubMed ID: 24002090
[TBL] [Abstract][Full Text] [Related]
10. Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.
Wang J; Zhang G; Bambara RA; Li D; Liang H; Wu H; Smith HM; Lowe NR; Demeter LM; Dykes C
J Virol; 2011 Oct; 85(20):10861-73. PubMed ID: 21835788
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors.
Gao Y; Paxinos E; Galovich J; Troyer R; Baird H; Abreha M; Kityo C; Mugyenyi P; Petropoulos C; Arts EJ
J Virol; 2004 May; 78(10):5390-401. PubMed ID: 15113918
[TBL] [Abstract][Full Text] [Related]
12. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
[TBL] [Abstract][Full Text] [Related]
13. Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
Gatanaga H; Ode H; Hachiya A; Hayashida T; Sato H; Oka S
Antimicrob Agents Chemother; 2010 Apr; 54(4):1596-602. PubMed ID: 20124001
[TBL] [Abstract][Full Text] [Related]
14. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
Gupta S; Fransen S; Paxinos EE; Stawiski E; Huang W; Petropoulos CJ
Antimicrob Agents Chemother; 2010 May; 54(5):1973-80. PubMed ID: 20194692
[TBL] [Abstract][Full Text] [Related]
15. In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors.
Wu H; Zhang XM; Zhang HJ; Zhang Q; Chen Z; Huang JD; Lee SS; Zheng BJ
AIDS Res Hum Retroviruses; 2015 Feb; 31(2):260-70. PubMed ID: 25482475
[TBL] [Abstract][Full Text] [Related]
16. Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients.
Hachiya A; Gatanaga H; Kodama E; Ikeuchi M; Matsuoka M; Harada S; Mitsuya H; Kimura S; Oka S
Virology; 2004 Oct; 327(2):215-24. PubMed ID: 15351209
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C.
Quan Y; Brenner BG; Marlink RG; Essex M; Kurimura T; Wainberg MA
AIDS Res Hum Retroviruses; 2003 Sep; 19(9):743-53. PubMed ID: 14585205
[TBL] [Abstract][Full Text] [Related]
18. Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe.
Shafer RW; Eisen JA; Merigan TC; Katzenstein DA
J Virol; 1997 Jul; 71(7):5441-8. PubMed ID: 9188616
[TBL] [Abstract][Full Text] [Related]
19. The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates.
Diallo K; Brenner B; Oliveira M; Moisi D; Detorio M; Götte M; Wainberg MA
Antimicrob Agents Chemother; 2003 Jul; 47(7):2376-9. PubMed ID: 12821504
[TBL] [Abstract][Full Text] [Related]
20. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
